(KDP) Keurig Dr Pepper - Overview
Sector: Consumer Defensive | Industry: Beverages - Non-Alcoholic | Exchange: NASDAQ (USA) | Market Cap: 39.619m USD | Total Return: -7.2% in 12m
Avg Turnover: 263M
EPS Trend: 98.3%
Qual. Beats: 0
Rev. Trend: 96.6%
Qual. Beats: 3
Warnings
Choppy
Tailwinds
Garp
Keurig Dr Pepper Inc. (KDP) is a leading North American beverage company operating a dual-model business that combines a diverse soft drink portfolio with a proprietary single-serve coffee ecosystem. The company manages a vertically integrated supply chain, manufacturing concentrates and finished goods for a vast network of owned and partner brands, including Dr Pepper, Snapple, and Green Mountain Coffee Roasters.
The business operates within the non-alcoholic beverage sector, which is characterized by high barriers to entry due to the extensive capital required for bottling and distribution infrastructure. KDP distinguishes itself from competitors by controlling both the hardware (Keurig brewers) and the consumables (K-Cup pods), a razor-and-blade strategy that fosters high customer retention and recurring revenue streams.
The company utilizes a multi-channel distribution strategy, reaching consumers through traditional retail outlets, fountain services, and direct-to-consumer e-commerce platforms. Investors looking for deeper fundamental insights may find additional value in reviewing the comprehensive data available on ValueRay. Founded in 1981 and headquartered in Texas, the firm maintains a significant presence in the U.S. Refreshment Beverages and U.S. Coffee segments.
- Strategic partnerships and distribution agreements drive market share in energy drink category
- Coffee pod volume fluctuates based on household penetration and consumer work-from-home trends
- Input cost inflation for aluminum and coffee beans impacts consolidated operating margins
- Market share gains in US Refreshment Beverages offset sluggish single-serve brewer demand
- International expansion in Mexico and Canada provides diversified revenue growth opportunities
| Net Income: 1.83b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -1.17 > 1.0 |
| NWC/Revenue: 77.35% < 20% (prev -31.09%; Δ 108.4% < -1%) |
| CFO/TA 0.03 > 3% & CFO 2.06b > Net Income 1.83b |
| Net Debt (26.5b) to EBITDA (4.38b): 6.05 < 3 |
| Current Ratio: 2.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.36b) vs 12m ago 0.11% < -2% |
| Gross Margin: 53.78% > 18% (prev 0.55%; Δ 5.32k% > 0.5%) |
| Asset Turnover: 26.72% > 50% (prev 28.90%; Δ -2.18% > 0%) |
| Interest Coverage Ratio: 4.06 > 6 (EBITDA TTM 4.38b / Interest Expense TTM 889.0m) |
| A: 0.18 (Total Current Assets 23.1b - Total Current Liabilities 10.0b) / Total Assets 73.1b |
| B: 0.08 (Retained Earnings 5.58b / Total Assets 73.1b) |
| C: 0.06 (EBIT TTM 3.61b / Avg Total Assets 63.4b) |
| D: 0.12 (Book Value of Equity 5.48b / Total Liabilities 44.0b) |
| Altman-Z'' = 1.94 = BBB |
| DSRI: 0.90 (Receivables 1.54b/1.56b, Revenue 16.9b/15.5b) |
| GMI: 1.03 (GM 53.78% / 55.25%) |
| AQI: 0.75 (AQ_t 0.64 / AQ_t-1 0.85) |
| SGI: 1.09 (Revenue 16.9b / 15.5b) |
| TATA: -0.00 (NI 1.83b - CFO 2.06b) / TA 73.1b) |
| Beneish M = -3.16 (Cap -4..+1) = AA |
As of May 30, 2026, the stock is trading at USD 30.03 with a total of 8,258,872 shares traded.
Over the past week, the price has changed by +4.34%,
over one month by +3.80%,
over three months by +0.05% and
over the past year by -7.21%.
Keurig Dr Pepper has received a consensus analysts rating of 4.10. Therefore, it is recommended to buy KDP.
- StrongBuy: 9
- Buy: 5
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 33.3 | 10.7% |
P/E Trailing = 21.5704
P/E Forward = 12.6582
P/S = 2.3383
P/B = 1.5684
P/EG = 0.9739
Revenue TTM = 16.9b USD
EBIT TTM = 3.61b USD
EBITDA TTM = 4.38b USD
Long Term Debt = 20.9b USD (from longTermDebt, last quarter)
Short Term Debt = 4.82b USD (from shortTermDebt, last quarter)
Debt = 27.4b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.73b
Net Debt = 26.5b USD (calculated: Debt 27.4b - CCE 898.0m)
Enterprise Value = 66.2b USD (39.6b + Debt 27.4b - CCE 898.0m)
Interest Coverage Ratio = 4.06 (Ebit TTM 3.61b / Interest Expense TTM 889.0m)
EV/FCF = 41.85x (Enterprise Value 66.2b / FCF TTM 1.58b)
FCF Yield = 2.39% (FCF TTM 1.58b / Enterprise Value 66.2b)
FCF Margin = 9.33% (FCF TTM 1.58b / Revenue TTM 16.9b)
Net Margin = 10.81% (Net Income TTM 1.83b / Revenue TTM 16.9b)
Gross Margin = 53.78% ((Revenue TTM 16.9b - Cost of Revenue TTM 7.83b) / Revenue TTM)
Gross Margin QoQ = 52.77% (prev 53.77%)
Tobins Q-Ratio = 0.90 (Enterprise Value 66.2b / Total Assets 73.1b)
Interest Expense / Debt = 3.24% (Interest Expense 889.0m / Debt 27.4b)
Taxrate = 24.37% (87.0m / 357.0m)
NOPAT = 2.73b (EBIT 3.61b * (1 - 24.37%))
Current Ratio = 2.31 (Total Current Assets 23.1b / Total Current Liabilities 10.0b)
Debt / Equity = 1.09 (Debt 27.4b / totalStockholderEquity, last quarter 25.3b)
Debt / EBITDA = 6.05 (Net Debt 26.5b / EBITDA 4.38b)
Debt / FCF = 16.79 (Net Debt 26.5b / FCF TTM 1.58b)
Total Stockholder Equity = 25.3b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.89% (Net Income 1.83b / Total Assets 73.1b)
RoE = 7.25% (Net Income TTM 1.83b / Total Stockholder Equity 25.3b)
RoCE = 7.82% (EBIT 3.61b / Capital Employed (Equity 25.3b + L.T.Debt 20.9b))
RoIC = 4.02% (NOPAT 2.73b / Invested Capital 67.9b)
WACC = 4.63% (E(39.6b)/V(67.1b) * Re(6.14%) + D(27.4b)/V(67.1b) * Rd(3.24%) * (1-Tc(0.24)))
Discount Rate = 6.14% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -4.49 | Cagr: -1.20%
[DCF] Terminal Value 73.68% ; FCFF base≈1.66b ; Y1≈1.51b ; Y5≈1.30b
[DCF] Fair Price = N/A (negative equity: EV 20.7b - Net Debt 26.5b = -5.87b; debt exceeds intrinsic value)
EPS Correlation: 98.30 | EPS CAGR: 6.86% | SUE: 0.82 | # QB: 0
Revenue Correlation: 96.65 | Revenue CAGR: 5.33% | SUE: 1.92 | # QB: 3
EPS current Quarter (2026-06-30): EPS=0.54 | Chg30d=-5.75% | Revisions=-57% | Analysts=13
EPS next Quarter (2026-09-30): EPS=0.63 | Chg30d=-0.28% | Revisions=-23% | Analysts=13
EPS current Year (2026-12-31): EPS=2.29 | Chg30d=-0.11% | Revisions=-9% | GrowthEPS=+11.5% | GrowthRev=+58.1%
EPS next Year (2027-12-31): EPS=2.52 | Chg30d=+0.21% | Revisions=+14% | GrowthEPS=+10.5% | GrowthRev=+13.7%
[Analyst] Revisions Ratio: -57%